Vaxxas adds three expert advisors to provide regulatory and manufacturing advice

Clinical stage biotechnology company Vaxxas, which is commercialising a needle-free vaccine delivery platform, has added three new expert advisors to its product development and strategy team. In a statement on Thursday morning (Australian time), the company said Dr Emilio Emini, Dr Nathalie Garcon, and Professor Paul Young will join Vaxxas as consultants to provide regulatory…

$7.2 million project using Vaxxas patches for JEV vaccination progresses

The Coalition for Epidemic Preparedness Innovations (CEPI) has approved progression of a $US 4.8 million ($7.2 million) program involving Vaxxas — a Brisbane-based, clinical-stage company developing a needle vaccine delivery platform — and an mRNA Japanese encephalitis vaccine (JEV) from SK bioscience. According to a statement from Vaxxas on Thursday, the program is to develop…

Manufacturing news briefs — stories you might have missed

Optiscan Imaging advances veterinary medtech Confocal microscopy manufacturer Optiscan Imaging has signed a Collaborative Research Agreement with the University of Minnesota College of Veterinary Medicine. The agreement follows a MOU with the university, and is a step in expanding the clinical applications of Optiscan’s confocal endomicroscope imaging system in veterinary medicine. The initial focus of…

Vaxxas needle free vaccines have great potential – study

Needle free vaccine delivery company Vaxxas‘s skin patch system is an attractive alternative to vaccine delivery via injection, according to a new study. Published in the journal Vaccine, the study said the company’s high-density microarray patch (HD-MAP) (pictured) was particularly attractive in a pandemic. Its’ use would alleviate the strain on healthcare systems by enabling…

Vaxxas awarded $5.4 million for typhoid vaccine clinical studies

Needle-free vaccine delivery company Vaxxas has announced it was awarded $5.4 million from charitable foundation Wellcome for initial studies and a  Phase I clinical trial of a potential second-generation typhoid vaccine delivered using Vaxxas’ technology. In a statement on Thursday, the Brisbane-based clinical-stage company said the project is expected to be completed within two years,…